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Abstract
Background: In vivo studies have shown grape seed-derived polyphenols (GSP) to benefit in recovery from muscle
injury by modulation of neutrophil infiltration into damaged tissue, thereby reducing secondary damage, as well as
by facilitating an early anti-inflammatory macrophage phenotype shift. The current study aimed to provide data in
this context from human models and to elucidate specific molecular targets of GSP.
Using a placebo-controlled, double-blind study design, eighteen normally healthy volunteers between the ages of
18–35 years old (13 female and 5 male) were orally supplemented with 140 mg/day of GSP for 2 weeks.
Blood samples (days 0 and 14) were comprehensively analysed for in vitro neutrophil chemokinetic capacity towards a
chemotaxin (fMLP) using a novel neutrophil migration assay, in combination with live cell tracking, as well as
immunostaining for neutrophil polarisation factors (ROCK, PI3K) at migration endpoint. Macrophage phenotype marker
expression was assessed using flow cytometry.
Results: fMLP induced significant chemokinesis (P < 0.01), validating our model. GSP did not exert a significant effect
on neutrophil chemokinesis in this non-compromised population, but tended to decrease overall ROCK expression
in fMLP-stimulated neutrophils (P = 0.06). Macrophage phenotype markers CD274 and MPO – indicators of a
pro-inflammatory M1 phenotype – seemed to be normalised relative to baseline expression levels after GSP treatment.
Conclusions: Current data suggest that GSP may have a modulatory effect on the ROCK-PI3K-PTEN system, but results
in this normal population is not conclusive and should be confirmed in a larger, more inflamed population. Potential
modulation of macrophage phenotype by GSP should be investigated further.
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Background
Arguably one of the most important and unique aspects
of inflammation, is the ability of phagocytic immune
cells to migrate through tissue to the site of injury or
pathogenic presence. Efficient, directionally accurate
movement of phagocytes to a site of injury will result in
faster repair by the minimum number of tissue-
infiltrating immune cells. This will not only lead to faster
resolution of inflammation, but will also result in less
secondary damage to otherwise healthy tissue (and thus
milder clinical symptoms of inflammation), as approxi-
mately 80% of secondary tissue injury has been ascribed
to the normally excessive response of neutrophils [1],
which includes the release of reactive oxygen species
and proteases [2]. Also, in terms of mononuclear phago-
cytes, macrophage phenotype M1 is recognised as a pro-
inflammatory phenotype capable of migration into tissue
(thus potentially exacerbating inflammation), while the
more anti-inflammatory M2 phenotype seems unable to
leave circulation to infiltrate tissue [3–5].
Grape seed-derived products – and polyphenols (GSP)
in particular – have received much attention in terms of
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its beneficial effects as anti-oxidant [6, 7], although it is
also known to have anti-inflammatory effects [8, 9].
Since the anti-inflammatory effects of grape-derived
products have received relatively less attention in terms
of research, despite the well-known links between oxida-
tive stress and inflammation, this was a particular focus
of the current study.
Despite several recent reviews highlighting the many
benefits to be derived from grape-derived products [9, 10],
the majority of data reported was from pre-clinical
models. In fact, in terms of human clinical results, data on
the anti-inflammatory effects of GSP is extremely limited
due to the recognised difficulty of translating natural
product benefits from animal models to human models in
research [10]. We have previously shown in pre-clinical
investigations in rodents, that GSP altered neutrophil mi-
gration into injured tissue, thereby limiting secondary
damage and the magnitude of the total inflammatory re-
sponse [7, 11, 12]. A second effect associated with GSP
treatment in vivo in rats, was the predominance of the
more anti-inflammatory M2 phenotype [12]. Also, in an in
vitro model of HIV-associated neuroinflammation, GSP
was shown to limit both pro-inflammatory cytokine
secretion and chemotaxin-induced human monocytic cell
migration across the blood brain-barrier [13]. Together,
these data suggest that GSP targets specific cellular sites
to beneficially alter the course of inflammation. However,
to our knowledge, these effects have not been investigated
in an in vivo human model and information on specific
molecular targets of GSP remain limited.
Therefore, the purpose of the current study was to ex-
pand on available knowledge by conducting an in vivo
supplementation study in human subjects. We hypothe-
sised that a 2-week supplementation with GSP would
improve the directional accuracy of neutrophils in re-
sponse to a chemotactic signal, via modulation of pro-
teins involved in the movement of these phagocytes. In
addition to our primary aim of investigating the effect of
GSP supplementation on cellular role players facilitating
neutrophil chemotactic movement, a second aim was
the design and implementation of a novel cell migration
assay with which to measure both functional outcome
(cell migration) and mechanisms (molecular role players)
in parallel and in the same cells, so that functional
capacity may be correlated with altered expression or
activation of cellular targets.
Methods
Ethical considerations
Application for registration of the natural product used
as medicine at the MCC was still pending at the time of
manuscript preparation (ref# 23128). This clinical trial
was registered with the South African Clinical Trials
Register (NHREC ref. #4242) and clinical trial medical
insurance was obtained through Stellenbosch University
(ref# PO309814).
Ethical clearance for all protocols was also obtained
from the Stellenbosch University Human Research Eth-
ics Committee (ref# M15/09/040) prior to subject re-
cruitment. The study was conducted according to the
SA MRC ethical guidelines, guidelines for good clinical
practice and the International Declaration of Helsinki.
All volunteers signed informed consent prior to entry
into the study.
Subject recruitment
A longitudinal, placebo-controlled, double-blind, human
in vivo study design was employed. Normally healthy,
non-smoking, recreationally active males and females
(n = 18, aged 18–25 years), not on any type of supple-
ment, and not suffering from known inflammatory dis-
eases, participated in the study. Subjects were instructed
to refrain from taking vitamin, anti-oxidant and anti-
inflammatory products and not permitted to perform any
strenuous exercise for a period of 14 days prior to initi-
ation of the protocol, as well as for the duration of the en-
tire protocol. A scientist not involved in the study, labelled
the placebo and GSP supplements using numerical code.
Supplement containers for both treatments were then ran-
domly dispensed to volunteers from one storage bin, as
they were recruited. This effectively divided volunteers
into two experimental groups, namely GSP supplemented
(n = 9) and placebo (n = 9), ensuring blinding of both
participant and investigators involved. All volunteers
completed the protocol (refer to Additional file 1 for
consort diagram and basic comparative subject demo-
graphics). Unblinding was only done at the point of statis-
tical analysis.
Supplementation protocol and blood collection
A commercially available GSP product (Oxipoven™,
Brenn-o-kem Pty Ltd., Tulbach, South Africa) was
employed in this study, and consisted of 45% proantho-
cyanidins, less than 5% monomers and the remainder
made up of long chain sugars and glycosides attached to
the oligomers, in capsule form. Placebo capsules were
prepared by the supplier following standard pharmaceut-
ical procedures as previously described [7], and was
identical to the GSP capsules, except for containing no
proanthocyanidins. After a 2-week pre-study wash out
phase, participants were supplied with GSP or placebo
supplements in capsule form, with instructions to con-
sume 2 capsules daily (to equal an intake of 140 mg of
proanthocyanidin B in GSP-supplementation group) for
a period of 2 weeks. Subjects were required to present
their supplements on sample collection days, for con-
firmation of compliance. On days 0, 7 and 14 blood
samples were obtained by venepuncture from a forearm
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vein, by an experienced phlebotomist. On days 0 (PRE)
and 14 (POST), 8 ml heparin blood and 8 ml ethylene
diamine tetra-acetic acid (EDTA) blood was obtained
from each patient, followed by immediate sample ana-
lysis (full blood count, neutrophil migration, immuno-
histochemistry staining, macrophage phenotyping).
In addition, given the reports of altered adhesion mol-
ecule expression after GSP use, as well as a recent report
of decreased iron content after mega doses of GSP [14],
automated full blood counts and clotting profiles were
performed at a commercial pathology laboratory
(Pathcare, Stellenbosch, South Africa) after the first
7 days of supplementation, to ensure volunteer safety.
(Results were within normal ranges for all participants,
with no effect of GSP – Additional file 2).
Neutrophil migration assay
Neutrophils were isolated from Lithium-heparin blood
using density gradient centrifugation with Histopaque
1.077 g/ml (Sigma-Aldrich, #10771) at 2:1 ratio and 6%
filtered dextran Cells were resuspended in RPMI and an
automated cell count performed (CellDyne 3700Cs,
Abbott Diagnostics, Germany), before adjusting cell
count to 1 × 106 cells/ml.
For cell migration, a novel migration assay was devel-
oped (Fig. 1). 75ul of isolated neutrophil suspension were
seeded to the bottom left hand corner of each well on an
8-well chamber slide (NUNC Lab-Tek II, cat#12–565-8.
Then, 75ul of 100μg/ml fMLP (#F3506, Sigma-
Aldrich) solution in RPMI 1640 with phenol red (Life
Technologies, #12633–020) was added to the top right
hand corner of each well. Neutrophil migratory paths
were visualized by combining time lapse images acquired
every 3 s for 40 min, using 20× magnification on an Olym-
pus Cell system IX-81 inverted fluorescent microscope
system with an F-view cooled CDC camera (Soft Imagin-
ing Systems) at 37 °C. Image J (Java Software) was used to
process the movement data and using the Mtrack J plugin,
neutrophil tracks were quantified by measuring the total
distance they moved (from starting point to endpoint), as
well as the linear distance covered (straight line from start
to finish).
Immunohistochemistry
At the end of image acquisition for live cell tracking, cells
were fixed with 4% (v/v) paraformaldehyde in PBS for
10 min before permeabilized before blocking with 1% BSA
(Bovine Serum Albumin Fraction V, Roche #10735078011)
for 20 min. This was followed by immunostaining using ap-
propriate conjugated antibodies (Anti-ROCK1, #AB205432,
Anti-PI3Kp110β, #AB202668, both Biocom Biotech) and
visualisation (LSM780 confocal microscope with ELYRA
S.1 Superresolustion platform (Carl Zeiss, Germany), using
ZEN Lite 2012 imaging software). Images were acquired in
the desired area of chemotaxis (point for contact of cell sus-
pension with chemotaxin-RPMI or control-RPMI). Mean
fluorescence intensity, as well as relative co-localisation of
ROCK and PI3K was determined. Co-localization is defined
as the presence of two or more different pixels occupying
the same space inside the neutrophil. The valid range is be-
tween zero and one, with 0 indicative of no co-localization
and 1 indicating 100% co-localisation. Values for co-
localisation was determined by the relative number of pixels
in a channel (PI3K or ROCK) compared to the total num-
ber of pixels above the threshold.
Flow cytometry
Monocytic cells were isolated from EDTA blood using
density centrifugation with Histopaque 1.077 g/ml
(sigma-Aldrich, #10771) at 2:1 ratio, followed by 42.56%
iso-osmotic 1.131 g/ml percoll (Sigma-Aldrich, #E0414)
solution in RPMI and phenol red at a 1.25:1 ratio. Pellets
of isolated cells were resuspended in Cytofix/Cytoperm
Fixation/Permeabilization Solution Kit (#554714, BD
Biosience), before phenotyping using flow cytometry and
appropriate antibodies (APC anti-CD86, PE anti-
myeloperoxidase (MPO), PE-Cy7 anti-CD274, SPC-Cy7,
CE anti-HLA-DR, PerCp-Cy5.5 anti-CD163 and BB515
anti-CD206, FITC anti-CD66b, PerCP-Cy5.5 anti-CD106
Fig. 1 Experimental layout of neutrophil migration assay in 8-well chamber slides
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(VCAM), and BV421 anti-CD54 (ICAM), all from BD
Bioscience).
Statistical analysis
Many of the parameters assessed in the current study,
have not been assessed before and thus variability was
not known, so that a statistical power estimation could
not be performed prior to the study. Subject number
was thus chosen following convention in the literature
for number of volunteers normally participating in simi-
lar human testing. In retrospect, statistical power was
poor, with an n = 80 calculated as the required number
of subjects to return a statistical power of > 80%. This
study should thus be considered a pilot study. Statistical
analysis was performed using Statistica (version 13.2).
Data was analysed for normalcy of distribution, where
after main effects of GSP treatment (GSP vs. placebo
comparison) was assessed by parametric and non-
parametric ANOVA as relevant and post hoc Fischer’s
LSD tests. Both absolute values for different parameters
at both time points, as well as values for change over
time, was compared between treatment groups. All
graphical data are presented as means and ± SEM
(standard error of means), while tables are presented as
means and ± SD (standard deviations), to follow conven-
tion for these parameters in the literature. A p-value
of < 0.05 was considered statistically significant.
Results
Neutrophil migration
Representative images are presented for the placebo- and
GSP-treated groups (Fig. 2a-h). Although no difference
was observed over time or between treatment groups,
there was a clear increase in cell migration under fMLP-
stimulated conditions, validating our model in terms of
sensitivity to the chemotaxin. Numerical data supports
this interpretation (Fig. 2i-j), indicating that fMLP stimula-
tion significantly increased both the total and linear
(ANOVA main effect of stimulation, both P < 0.05) neu-
trophil distance travelled when compared to unstimulated
a b c d
e f g h
i j
Fig. 2 Representative images (a-h) of placebo and GSP-treated neutrophil chemokinesis and pooled (main effects ANOVA) quantitative results
(i-j) demonstrates the significant effect of fMLP-stimulation, irrespective of treatment, on chemokinetic movement of neutrophils. The migration
pathway tracked for the neutrophils is seen by the coloured lines on each image. The white arrow indicate the expected/ideal direction of
movement towards the chemoattractant. Images were acquired at 200× magnification (n = 9 per group, for all conditions and time point groups,
as presented in Table 1). Numerical data are expressed as means and standard error of means (SEM). Statistical analysis: ANOVA and post hoc
Fischer’s LSD test
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conditions. Group-specific quantitative results again con-
firmed visual results, with no significant treatment or time
effect (Table 1).
Molecular role players facilitating neutrophil migration
GSP supplementation had no apparent effect on neutro-
phil surface expression of CD66b, ICAM-1 or VCAM-1
(Fig. 3a-c). Representative flow cytometry scatter plots and
fluorescence graphs are presented in Additional file 3.
In terms of intracellular role players, although there is
no clear evidence of a treatment effect from qualitative
data, both ROCK and PI3K seemed to occur diffusely
through in the cell in the absence of a stimulus, with
relatively more localised expression and increased co-
localisation of ROCK and PI3K under stimulated condi-
tions (Fig. 4a-h). Quantitative data showed that both
ROCK and PI3K expression were highly variable be-
tween individuals, as well as over time (Fig. 4i-j).
From current pilot data, no statistically significant effect
of GSP on expression levels of either ROCK or PI3K was
evident, although there was a tendency for an interaction
effect (P = 0.06) of treatment, time and fMLP stimulation
for ROCK specifically (Fig. 4j), suggesting a modified ROCK
response to fMLP stimulation after GSP treatment. In order
to further explore this possibility, co-localisation patterns of
ROCK and PI3K expression was analysed. fMLP-
stimulation increased the relative portion of ROCK that
co-localised with PI3K (ANOVA main effect, P < 0.05) –
as expected, validating the model even further. Interest-
ingly, for both PRE groups, as well as PLA POST, ROCK
co-localisation on average increased by more than 25%
(Fig. 4k), while POST GSP ROCK co-localisation did not
reflect a similar change on stimulation. Although this re-
sult is not conclusive due to the low statistical power in
this study, the possibility that ROCK expression levels –
and perhaps also its specific locality within the cell – may
be a target via which to achieve a modulatory effect in
terms of inflammation, warrants further investigation.
Macrophage phenotype
The expression of macrophage phenotype markers in
peripheral blood monocytic cells from treatment groups
over time are presented in Table 2. Representative flow
cytometry scatter plots are provided in Additional file 4.
No main effect of treatment or over time was seen,
although it should again be noted that both intra- and
inter-individual variations were quite large. Interestingly,
for CD274 and MPO – both pro-inflammatory
indicators – the PRE vs POST values were inversely cor-
related in the GSP-treated group only (Fig. 5, P < 0.05).
Discussion
Although the data presented is statistically underpowered
due to low subject number and high inter- and intra-
individual variability, it does provide some insights which
may inform on future study design. Current data firstly
present a novel method by which in vitro cell migration
may be assessed in parallel for both functional capacity and
molecular cellular role players, using the exact same cell
sample. Secondly, data suggest a role for GSP modulation
of cellular role players involved in neutrophil chemotactic
movement that is in line with results from animal models
and thus warrants further investigation. No effect on migra-
tion was observed for GSP treatment. Although several re-
ports of positive effects of polyphenols and GSP on
inflammation exist [7, 11, 12] there is relative paucity of in-
formation on neutrophil migration and chemokinesis after
in vivo GSP supplementation in humans. In contrast to re-
ported in vitro results, current data showed high variability,
which may be attributed to different factors, of which at
least some are related to study design. Firstly, neutrophils
which are isolated and then treated with GSP are exposed
to a more controlled environment (in terms of dose of GSP,
time of exposure and potential confounding factors), which
allows for direct effects of GSP to be detected more readily.
In contrast, in in vivo studies, the net effects of GSP is
assessed after the supplement has been metabolised – a
process which depends on the inherent metabolic rate of
each individual assessed. Furthermore, the neutrophil as
the first line of defence is arguably the most excitable im-
mune cell, so that it may be activated during the supple-
mentation period for various reasons unrelated to the study
intervention. Thus, the relatively larger inter- and intra-
individual variations may mask effects.
Table 1 Total and linear distances travelled by fMLP-stimulated neutrophils collected from individuals before and after 2-weeks of
placebo or GSP supplementation. Values are expressed as means and standard deviations (SD)
Neutrophil chemokinetic
indicators
PLACEBO GSP
Unstimulated Stimulated Unstimulated Stimulated
PRE POST PRE POST PRE POST PRE POST
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Total Distance (um) 65.08 (37.30) 73.26 (35.46) 83.32* (54.66) 143.21* (60.77) 92.64 (56.14) 81.24 (43.68) 112.90* (69.78) 155.78* (67.11)
Linear distance (um) 12.67 (13.93) 16.61 (10.470 26.66a (16.57) 53.19 (29.16)* 13.54 (10.71) 13.52 (42.91) 35.30a (25.27) 42.91* (29.01)
Statistical analysis: ANOVA and post hoc Fischer’s LSD test, (n = 9 per group)
*P < 0.05 at least, effect of stimulation; aeffect of stimulation, P = 0.06
No effect of time or treatment
Smith et al. Journal of Inflammation  (2018) 15:2 Page 5 of 10
In order to better understand the variation, a reliability
value calculation was performed on both total and linear
distance, both between individuals and for the same in-
dividuals over time. Briefly, reliability was calculated –
the inter-individual repeatability value was 0.61 and 0.43
for total and linear distance respectively, and the intra-
individual repeatability value 0.39 and 0.57. This implies
that inter-person variation contributed to 61% and 43%
of the variability in current data for these two parame-
ters. Statistical power could therefore be improved by
addition of more subjects, or increasing the effect size
(i.e. using a population more in need of anti-oxidant or
anti-inflammatory modulation, such as an aged or in-
flamed population). A subsequent power analysis indi-
cated that more than 80 subjects would be required to
provide sufficient statistical power – a number that is not
feasible, given the high cost of analyses. Furthermore,
given the fact that day-to-day variation is shown to con-
tribute 39 and 57% of variability for total and linear dis-
tance respectively, even data from a bigger group is likely
to be complex to interpret in a longitudinal study design.
Rather, we recommend that in vivo studies should either
be of cross-sectional design – i.e. focus on acute effects on
potential molecular targets – or that a very controlled
clinical trial should be conducted, during which not only
food intake, but also exposure to potential antigens, can
be limited. Alternatively, a population with a poorer base-
line inflammatory profile may be more ideal to illustrate
anti-inflammatory effects, as the expected effect size
would be larger. Therefore, although no significant effect
was seen in terms of neutrophil movement parameters,
given this variability, it does not exclude that GSP may
have effects at molecular level.
Since GSP had no significant effect on neutrophil che-
mokinesis in the healthy population in this study – who
probably had limited reserve for improvement of oxida-
tive stress or inflammatory status – these results cannot
conclusively inform on effects of GSP on neutrophil
migration. Using conventional techniques, i.e. migration
assessment in a closed system, the conclusion may have
incorrectly been made that GSP had no effect on migra-
tion. However, the immunochemistry results obtained
from the migrating cells suggest differently, significantly
altering the interpretation here.
For example, the consistent aberration in ROCK-
related parameters in the GSP-treated group, suggests
modulatory effect of GSP on neutrophil cellular parame-
ters in the context of the ROCK-PI3K-PTEN pathway.
Neutrophil polarization is a process that causes neutro-
phils to undergo a mechanical shape change (elongation)
which demonstrate a clear leading and tail end of the
cell [15]. In terms of the role players assessed in this
context, we hypothesised that GSP may have its effect by
separating localisation sites of PI3K (to the front) and
ROCK (to the rear) in a migrating cell, to improve
overall migration capacity and directional accuracy.
Futhermore, in terms of the literature on changes in
ROCK expression, a decrease has been linked to in-
creased recruitment and migration of neutrophils [16].
In contrast, the loss of ROCK has been associated with
neutrophil tail retraction defects [17, 18], suggesting an
optimal level of ROCK expression is required for max-
imum migration capacity. Current data suggests that
GSP may modify the ROCK response to fMLP stimula-
tion, although more research is required for a firm con-
clusion to be made. This is in line with our hypothesis,
and may further suggest that GSP may act as such an
“optimising modulator” of ROCK. ROCK is known to
regulate PTEN – whose role is to dephosphorylate PIP3
to PIP2 and maintain the anterior-posterior PIP3
gradient [19], which is vital for maintaining directional
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Fig. 3 Effect of 2-week in vivo placebo and GSP supplementation
on neutrophil protein expression: (a) CD66b, (b) ICAM-1 and (c)
VCAM-1. Data are expressed as means and standard error of means.
(n = 9 per group)
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Fig. 4 Effect of GSP treatment on neutrophil ROCK and PI3K expression (n = 9 per group). Representative images are presented in (a-h), with
ROCK stained green and PI3K red. Yellow is indicative of co-localization. DAPI (1:20 dilution) stained neutrophil nuclei blue. Images were taken at
200× magnification. Numerical data for ROCK (i) and PI3K (j) expression, as well as ROCK co-localisation with PI3K (k) and PI3K co-localisation with
ROCK (l) are expressed as means and standard error of means (SEM). Statistical analysis: ANOVA and post hoc Fischer’s LSD test
Table 2 Effects of placebo and GSP treatment on basal expression of macrophage markers in peripheral blood monocytic cells. Data
are expressed as means and standard deviation (SD)
Macrophage phenotypic
markers
PLA PRE PLA POST GSP PRE GSP POST
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
CD86 (MFI) 1071 (494) 1345 (469) 1086 (437) 1284 (85)
HLA-DR (MFI) 1145 (602) 1513 (608) 827 (403) 1131 (692)
CD274 (MFI) 601(371) 670 (405) 558 (331) 450 (198)
MPO (MFI) 1940 (1427) 1819 (1813) 1839 (1021) 1869 (1659)
CD206 (MFI) 1896 (1621) 2027 (1204) 1474 (1408) 1440 (953)
CD163 (MFI) 465 (187) 543 (187) 487 (219) 488 (195)
Intracellular IL-10 (MFI) 257 (171) 196 (66) 178 (47) 199 (97)
Abbreviation: MFI Median Fluorescent Intensity
Statistical analysis: LSD test (ANOVA), (n = 8 placebo, n = 9 GSP), no significant difference of time or treatment was evident
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accuracy [20, 21] and its expression level is positively as-
sociated with neutrophil migration and the recruitment
of neutrophils [22, 23]. Furthermore, current results sug-
gest that a greater extent of co-localization of ROCK
with PI3K may occur under stimulated conditions than
under unstimulated conditions (≈25%, ANOVA main ef-
fect, P < 0.05). Interestingly, the same sensitivity was not
seen for PI3K. Although the isoform of PI3K assessed in
the current study – p110β – has been implicated in cell
migration [24], the p110γ isoform has been demon-
strated to be more sensitive than the p110β to experi-
mental G protein-coupled receptor mediated activation
[25], which may account for the seemingly lower sensi-
tivity of PI3K to ROCK here. This is a limitation of the
current study and should be improved on in subsequent
trials to ensure optimal sensitivity and relevance. No
other literature is available on PI3K and ROCK expres-
sion on actively migrating neutrophils, but in light of the
increased co-localisation of these parameters after fMLP
stimulation, data may suggest increased capacity for cell
polarisation after GSP treatment. Importantly, this sup-
ports our interpretation that GSP may not necessarily
affect total ROCK or PI3K expression levels, but may
rather optimise the sites in the cell where they are local-
ised. The decrease in ROCK localisation with PI3K may
indeed point towards an improved, GSP-associated po-
larisation of the cell to have ROCK focused in the rear
and PI3K focused in the leading edge of the cell, which
should improve migratory economy, as movement will
be more directed.
In terms of cell adhesion, plasma levels of soluble ad-
hesion molecules is the more commonly used protocol
for assessing cellular adhesion dynamics in the recent
literature. An obvious limitation of this approach is that
the source of adhesion molecules in plasma cannot be
deduced from this, since the shedding of expression
markers can be attributed to various cell types. Results
in the present study indicated that GSP does not have a
significant effect on cellular expression of CD66b,
ICAM-1 or VCAM-1. Although one would expect an
anti-inflammatory product to exhibit significant modula-
tory effects on adhesion, our result is in line with the
data of Schleimer et al. [26], who similarly reported no
change in neutrophil adhesion molecule expression after
treatment with IL-4, which is also a known anti-
inflammatory modality [27]. In contrast, an in vitro
study on the effects of red grape polyphenols on some of
these markers [28], reported decreased ICAM-1 protein
and gene expression. However, this effect of the polyphe-
nols were only evident after stimulation of the (HUVEC)
cells to lipopolysaccharide (LPS), which is a known up-
regulator of these adhesion molecules [29–31]. Together,
these results suggest that assessment of anti-inflammatory
effects under basal conditions is not reflected by cellular
adhesion protein expression, and thus that plasma adhe-
sion molecule expression modulation may then reflect
modulation of adhesion molecule expression at the level
of the endothelium. This in itself is interesting, for two
reasons. Firstly, increased lymphocyte adhesion molecule
expression has been linked to hypercoagulability and in-
creased risk for atherosclerosis [32]. Secondly, GSP has
been reported to decrease VCAM-1 expression [8, 33].
Together, this suggests that while cell adhesion are not
compromised – i.e. immune function is maintained in this
context – GSP may have additional benefit in the context
of atherosclerosis by modification of the endothelium
itself. This opens up a new avenue for investigation in the
preventative medicine niche.
Finally, our result indicate for the first time in humans,
that GSP treatment may indeed exert direct effects on
peripheral monocytic cells to limit inflammatory infiltra-
tion into tissue, a result we have previously reported in
rats with acute skeletal muscle damage-associated in-
flammation [7, 11, 12] as well as in an in vitro simula-
tion of human HIV-associated inflammatory infiltration
across the blood brain barrier [13]. Specifically, the sig-
nificant inverse correlation between PRE and POST
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expression levels of both CD274 and MPO within the
GSP group only, suggests an adaptogenic role for GSP –
i.e. effectively being able to decrease relatively higher M1
protein expression levels while increasing relatively
lower levels. These results, reported under unstimulated
conditions, are especially remarkable in terms of the po-
tential effect of GSP, if one considers that significant
changes in M1/M2 markers have only ever been re-
ported after stimulation of cells [34]. Interestingly, type
M1 macrophages are known secrete pro-inflammatory
cytokines as well as ROS. In excess, ROS can be
extremely detrimental to the immune cell itself [35].
Hence, this suggested modulation of M1 phenotype ex-
pression by GSP is of importance, as it suggest a poten-
tial additional avenue by which GSP may indirectly exert
its anti-oxidant effect.
Conclusions
In conclusion, we provide the first evidence of an
immunomodulatory role for GSP in a human in vivo
supplementation model, in support of data from animal
models. The limited beneficial effects already evident in
this pilot study in a healthy, young population – and the
absence of any adverse effects – warrants further investi-
gation of GSP via an appropriately powered clinical trial
in more compromised populations, such as in aged or
chronically inflamed individuals.
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